Match!
Edwin P. Alyea
Harvard University
ImmunologyHematopoietic stem cell transplantationGraft-versus-host diseaseTransplantationMedicine
455Publications
72H-index
15.5kCitations
What is this?
Publications 469
Newest
#1Eduardo Espada (Harvard University)H-Index: 1
#2Matthew P. Cheng (Harvard University)H-Index: 10
Last. Mahasweta Gooptu (Harvard University)H-Index: 4
view all 20 authors...
Clinical disease caused by BK virus reactivation is a frequent complication of allogeneic hematopoietic cell transplantation (HCT). Because of the lack of effective antiviral agents, BK virus-specific T cells are emerging as a potential therapy for BK virus disease, but the immune response to BK virus after allogeneic HCT has not been well characterized. Our study describes reconstitution of BK virus-specific T-cell immunity in 77 adult patients after HCT. All patients had urinary symptoms, and ...
Source
#1Krisstina L. Gowin (UA: University of Arizona)
#2Karen K. Ballen (University of Virginia Health System)H-Index: 4
Last. Michael Green (Duke University)H-Index: 4
view all 68 authors...
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of tra...
Source
#1Christopher S. Hourigan (NIH: National Institutes of Health)H-Index: 15
#2Laura W. Dillon (NIH: National Institutes of Health)H-Index: 3
Last. Mitchell E. Horwitz (Duke University)H-Index: 30
view all 22 authors...
PURPOSEPatients with acute myeloid leukemia (AML) in remission remain at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) s...
2 CitationsSource
#1Pavan Bachireddy (Brigham and Women's Hospital)H-Index: 14
#2Christina Ennis (Harvard University)
Last. Natalie Bavli (UTSW: University of Texas Southwestern Medical Center)
view all 25 authors...
Resistance to the graft-versus-leukemia (GvL) effect remains the major barrier to successful allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aggressive hematologic malignancies. The basis of GvL resistance for advanced lymphoid malignancies remains incompletely understood. We hypothesized that for patients with chronic lymphocytic leukemia (CLL) treated with allo-HSCT, leukemic cell-intrinsic features shape GvL outcomes by directing the evolutionary trajectories of CLL cells. ...
Source
#1Zachariah DeFilipp (Harvard University)H-Index: 10
#2Shuli Li (Harvard University)H-Index: 14
Last. Corey Cutler (Harvard University)H-Index: 73
view all 21 authors...
In this multicenter Phase 2 single arm study, we substituted low dose total body irradiation (TBI) for antithymocyte globulin (ATG) in a reduced intensity conditioning regimen with the intent to lower the risk for viral infections after double umbilical cord blood (UCB) transplantation. The conditioning regimen consisted of fludarabine (30 mg/m2/day, Day −7 to −2), melphalan (100 mg/m2/day, Day −1), and TBI (200cGy, Day 0). Graft-versus-host disease prophylaxis was sirolimus and tacrolimus. Thir...
Source
Purpose We previously demonstrated poor outcomes of patients with acute myeloid leukemia (AML) with antecedent myeloproliferative neoplasms (MPN) undergoing allogeneic hematopoietic stem cell transplantation (HCT) (Gupta et al, BBMT, 2019; abstract 140). In particular, we did not find any difference in outcomes of patients who received transplant “in remission” defined as blood and bone marrow blasts Patients and Methods Of the 177 patients with post MPN AML identified in the Center for Internat...
Source
#1Benedetta Rambaldi (UNIPV: University of Pavia)
#1Benedetta RambaldiH-Index: 5
Last. Edwin P. AlyeaH-Index: 72
view all 15 authors...
Haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide (PTCy) as graft versus host disease (GVHD) prophylaxis is frequently used for patients who do not have HLA-identical donors. However, the effect of PTCy on immune reconstitution (IR) has not been studied extensively in large prospective cohorts, despite a high incidence of early viral infections. We quantified IR in 60 patients after haplo-HCT with PTCy, mycophenolate mofetil and tacrolimus (TAC) ...
Source
#1Clinton W. Lewis (Auckland City Hospital)
#2Haesook T. Kim (Harvard University)H-Index: 57
Last. Vincent T. Ho (Harvard University)H-Index: 71
view all 16 authors...
ABSTRACT fludarabine with intravenous busulfan at doses of 3.2 mg/kg (Flu/Bu1) or 6.4mg/kg (Flu/Bu2) Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication of hematopoietic stem cell transplantation (HCT) that is felt to be triggered, at least in part, by damage to the liver sinusoidal endothelium from cytotoxic conditioning regimens. Accordingly, the incidence of VOD/SOS after reduced-intensity conditioning (RIC) HCT is low compared with myeloablative...
Source
#1Zachariah DeFilipp (Harvard University)H-Index: 10
#2Richard G. Ancheta (Scripps Health)H-Index: 2
Last. Wael Saber (Center for International Blood and Marrow Transplant Research)H-Index: 28
view all 50 authors...
Abstract It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myeloid leukemia (CML). In this registry study, we analyzed clinical outcomes of 390 adult patients with CML transplanted from 2007-2014 who received maintenance TKI following HCT (n=89) as compared to no TKI maintenance (n=301), as reported to the Center for Internat...
Source
#1Sarah Ann Schmidt (OU: University of Oklahoma)
#2Ying Liu (Center for International Blood and Marrow Transplant Research)H-Index: 1
Last. Daniel J. Weisdorf (UMN: University of Minnesota)H-Index: 108
view all 36 authors...
Abstract Treatment for relapse of chronic myeloid leukemia (CML) following hematopoietic cell transplantation (HCT) includes tyrosine kinase inhibitors (TKI) with or without donor lymphocyte infusions (DLI), however the most effective treatment strategy is unknown. This study was performed through the Center for International Blood and Marrow Transplant Research (CIBMTR) database. We retrospectively reviewed all patients reported to the CIBMTR registry from 2002-2014 who underwent HCT for CML an...
Source
12345678910